度洛西汀治疗帕金森病患者疲劳的临床效果

doi:10.20047/j.issn1673-7210.2023.20.22

Abstract
Figure/Table
References (28)
Related Citation (15)

Download: PDF (588 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the clinical effect of Duloxetine in treating Parkinson disease fatigue. Methods From July 2020 to March 2022, 58 patients with Parkinson disease fatigue who were treated and followed up in the Department of Neurology of the First Hospital of Zhangjiakou they were divided into intervention group 1 and intervention group 2 by random number table method, with 29 patients in each group. Intervention group 1 was treated with parkinson’s drugs, and intervention group 2 was treated with Duloxetine on this basis. Fatigue scores, depression scores and serum levels of 5-hydroxytryptamine (5-HT) and norepinephrine (NE) before and after treatment were compared between the two groups. Results The overall analysis showed that there were significant differences between groups, time point comparison and interaction (P＜0.05). Intra-group comparison: the FS-14 score and depression score between the two groups at each time point and the differences were statistically significant (P＜0.05). Inter-group comparison: the FS-14 score and depression score of intervention group 2 were lower than those of intervention group 1 at each time point after treatment, and the differences were statistically significant (P＜0.05). The fatigue control effect of intervention group 2 was better than that of intervention group 1, the difference was statistically significant (P＜0.05). Intra-group comparison: the 5-HT and NE levels between the two groups at each time point and the differences were statistically significant (P＜0.05). Inter-group comparison: After treatment, the levels of 5-HT and NE in intervention group 2 were higher than those in intervention group 1 at each time point, and the differences were statistically significant (P＜0.05). Conclusion On the basis of optimizing Parkinson’s drug, Duloxetine can improve fatigue control effect by regulating serum 5-HT and NE levels, and its effect on fatigue improvement is not dependent on improving depressive symptoms.

Key words： Duloxetine Mental fatigue Physical fatigue 5-hydroxytryptamine Norepinephrine

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Shen HOU Qing SHAO Qiuying ZHANG Lian GONG Yuanyuan LYU Haixia YANG Ting YUE Shumin▲

Cite this article:

WANG Shen HOU Qing SHAO Qiuying ZHANG Lian GONG Yuanyuan LYU Haixia YANG Ting YUE Shumin▲. Clinical effect of Duloxetine on fatigue in patients with Parkinson disease[J]. 中国医药导报, 2023, 20(20): 105-108.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2023.20.22 OR https://www.yiyaodaobao.com.cn/EN/Y2023/V20/I20/105

[1] 张贺，姜立刚.帕金森病非运动症状研究现状[J].中国实用神经疾病杂志，2021，24（1）：72 -76.
[2] 万赢，肖仁清，赵嘉豪，等.帕金森病运动并发症风险分层治疗方案的疗效评价[J].中华医学杂志，2022，102（7）：491-498.
[3] 王佳彬，沈晓明，马云枝，等.帕金森病中西医研究进展[J].中国实验方剂学杂志，2022，28（1）：248-250.
[4] 王占芬，任爱兵，王英，等.普拉克索，氟西汀，度洛西汀治疗帕金森病伴发抑郁状态的随机对照研究[J].临床内科杂志，2020，37（2）：3.
[5] 《中国帕金森病的诊断标准（2016版）》发布[J]. 中华医学信息导报，2016，31（8）：9.
[6] 荆晓雷，庄红霞，岳佳佳，等.帕金森疲劳程度量表的汉化及信效度检验[J].护理研究，2020，34（23）：4.
[7] Chalder T，Berelowitz G，Pawlikowska T，et al. Development of a Fatigue Scale [J]. J Psychosom Res，1993，37（2）：147-153.
[8] 王冰，徐军，汤修敏.帕金森病统一评分量表信度和效度研究[J].山东医药，2009，49（28）：88-89.
[9] 汤毓华，张明园.汉密顿抑郁量表（HAMD）[J].上海精神医学，1984（2）：61-64.
[10] Cockrell JR，Folstein MF. Mini-mental state examination （MMSE）[J]. Psychopharmacol Bull，1988，24（4）：689-692.
[11] 李利，范振毅，李达，等.帕金森病伴发疲劳的识别和管理研究进展[J].中华神经科杂志，2022，55（6）：6.
[12] 姚璇，时晶，李婷，等.帕金森病疲劳症状中医证候要素特征分析[J].天津中医药，2021，38（10）：1259-1262.
[13] Skorvanek M，Nagyova I，Rosenberger J，et al. Clinical determinants of primary and secondary fatigue in patients with Parkinson’s disease [J]. J Neurol，2013，260（6）：1554-1561.
[14] Braak H，Rub U，Gai WP，et al. Idiopathic Parkinson’s disease：Possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen [J]. J Neural Transm，2003，110（5）： 517-536.
[15] 毛成洁.帕金森病疼痛和疲劳的临床研究[D].苏州：苏州大学，2015.
[16] 张敏.度洛西汀联合米氮平治疗老年抑郁症伴失眠的临床分析[J].老年医学与保健，2021，27（2）：355-358.
[17] 王秀秀，田玉玲，王芳.帕金森病疲劳的影响因素及补充维生素D的意义[J].临床与病理杂志，2021，41（1）：89-96.
[18] 黄飞，姜祥智.西酞普兰与度洛西汀治疗抑郁症的性别与年龄差异[J].青岛大学医学院学报，2019，55（1）：95- 98.
[19] 武冬冬，杜危，龙云飞，等.帕金森病患者主观认知减退的临床特征及其与情感症状的关系初探[J].中华神经科杂志，2022，55（3）：191-195.
[20] 李智敏，高立叶，孙立华.基于神经递质水平的齐拉西酮联合度洛西汀治疗老年脑卒中后抑郁的疗效探讨[J].药物评价研究，2022，45（3）：532-537.
[21] 景何灵，蒋家美.帕金森病患者抑郁及生活质量的影响因素分析[J].国际神经病学神经外科学杂志，2021，48（4）：327-332.
[22] 蒋莹，冯涛，房进平，等.帕金森病伴发不同程度抑郁的影响因素分析[J].中国医药导报，2021，18（20）：59-61， 65.
[23] 沈海玲.无缝隙护理干预对帕金森病患者运动功能及心理状态的影响[J].中国医药科学，2021，11（10）：138-140， 153.
[24] 杨新新，李中军，王钰乔.帕金森病疲劳症状特点及其与其他症状的相关分析[J].中国现代神经疾病杂志，2018， 18（8）：614-620.
[25] 钟真真，申佩，高云春.原发性帕金森病患者非运动症状的临床特点[J].中国实用神经疾病杂志，2022，17（25）：4-8.
[26] 杨雅玲，卢武生，刘华斌，等.帕金森病非运动症状相关基因多态性研究进展[J].中国临床研究，2021，34（3）：409-412.
[27] Pavese N，Metta V，Bose SK，et al. Fatigue in Parkinson’s disease is linked to striatal and limbic serotonergic dysfunction [J]. Brain，2010，133（11）： 3434-3443.
[28] 何饶丽，陈丽娜，蔡国恩，等.帕金森病患者运动症状起病侧对睡眠的影响[J].中华神经科杂志，2021，54（12）：1241-1248.